In today’s session Accelerate Diagnostics Inc (AXDX) registered an unusually high (1,016) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious AXDX increase. With 1,016 contracts traded and 5714 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: AXDX161216C00030000 closed last at: $0.95 or 18.7% up. About 18,921 shares traded hands. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 85.69% since April 22, 2016 and is uptrending. It has outperformed by 80.28% the S&P500.
Analysts await Accelerate Diagnostics Inc (NASDAQ:AXDX) to report earnings on March, 8. After $-0.34 actual EPS reported by Accelerate Diagnostics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Accelerate Diagnostics Inc (NASDAQ:AXDX) Ratings Coverage
Out of 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Accelerate Diagnostics has been the topic of 5 analyst reports since August 25, 2015 according to StockzIntelligence Inc. Piper Jaffray initiated the shares of AXDX in a report on Wednesday, December 16 with “Overweight” rating. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) has “Overweight” rating given on Thursday, March 24 by JP Morgan. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) earned “Neutral” rating by BTIG Research on Tuesday, August 25. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) has “Overweight” rating given on Tuesday, August 9 by JP Morgan. The rating was initiated by William Blair with “Outperform” on Friday, January 8.
According to Zacks Investment Research, “Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado.”
Insitutional Activity: The institutional sentiment decreased to 1.03 in 2016 Q2. Its down 0.11, from 1.14 in 2016Q1. The ratio dropped, as 8 funds sold all Accelerate Diagnostics Inc shares owned while 28 reduced positions. 11 funds bought stakes while 30 increased positions. They now own 12.54 million shares or 1.89% less from 12.78 million shares in 2016Q1.
Stifel Finance Corporation accumulated 0% or 33,840 shares. Thompson Davis And Inc has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). Blair William & Il accumulated 0.04% or 268,704 shares. Susquehanna International Group Llp reported 32,974 shares or 0% of all its holdings. California Public Employees Retirement holds 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 32,200 shares. First Republic Inc last reported 0.11% of its portfolio in the stock. The Illinois-based Ubs Asset Management Americas has invested 0% in Accelerate Diagnostics Inc (NASDAQ:AXDX). Blackrock Institutional Na reported 631,062 shares or 0% of all its holdings. The New York-based Qs Investors Llc has invested 0% in Accelerate Diagnostics Inc (NASDAQ:AXDX). Cap Advisers Ltd Liability Com, a California-based fund reported 10,715 shares. Oaktop Mgmt Ii Limited Partnership last reported 125,000 shares in the company. Manufacturers Life The has invested 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX). California State Teachers Retirement holds 0% of its portfolio in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 48,311 shares. Moreover, Credit Suisse Ag has 0% invested in Accelerate Diagnostics Inc (NASDAQ:AXDX) for 64,771 shares. Metropolitan Life Insur Ny owns 17,271 shares or 0% of their US portfolio.
Insider Transactions: Since June 8, 2016, the stock had 5 insider buys, and 0 selling transactions for $4.40 million net activity. SCHULER JACK W also bought $1.43M worth of Accelerate Diagnostics Inc (NASDAQ:AXDX) on Wednesday, June 8.
Accelerate Diagnostics, Inc. is an in vitro diagnostics firm engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The company has a market cap of $1.28 billion. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. It currently has negative earnings. The Firm is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System , intended for the diagnosis of infectious pathogens.
More important recent Accelerate Diagnostics Inc (NASDAQ:AXDX) news were published by: Nasdaq.com which released: “Accelerate Diagnostics to Present at the Piper Jaffray 28th Annual Healthcare …” on November 22, 2016, also Globenewswire.com published article titled: “Accelerate Diagnostics Submits De Novo Request to FDA for Accelerate Pheno …”, Benzinga.com published: “Cramer Likes Accelerate Diagnostics Inc” on April 03, 2016. More interesting news about Accelerate Diagnostics Inc (NASDAQ:AXDX) was released by: Seekingalpha.com and their article: “Accelerate Diagnostics: Potential Upside With Accelerated Pathogen Diagnostics” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.